The limiting factor for successful hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated attack of recipient tissue by donor T cells contained in the transplant. Mouse models of GvHD have provided important insights into the pathophysiology of this disease, which have helped to improve the success rate of HSCT in humans. The kinetics with which GvHD develops distinguishes acute from chronic GvHD, and it is clear from studies of mouse models of GvHD (and studies of human HSCT) that the pathophysiology of these two forms is also distinct. Mouse models also further the basic understanding of the immunological responses involved in GvHD pathology, such as...
<div><p>Mice bearing a “humanized” immune system are valuable tools to experimentally manipulate hum...
Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment for hematologic malignan...
Despite considerable progress in allogeneic hematopoietic cell transplantation (allo-HCT) has been a...
AbstractOver the last 50 years, mouse models of bone marrow transplantation have provided the critic...
AbstractChronic graft-versus-host-disease (cGVHD) is a major barrier to successful allogeneic hemato...
Graft-vs-host disease (GVHD) is the most common cause of non-relapse mortality following allogeneic ...
Over the last 50 years, mouse models of bone marrow transplantation have provided the critical links...
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for hematologic malig...
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell trans...
AbstractChronic graft-versus-host-disease (cGVHD) is a major barrier to successful allogeneic hemato...
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell trans...
Bone marrow transplantation (BMT) is the only therapeutic option for many hematological malignancies...
The last 6 decades have seen major advances in the understanding of immunologic diseases, driven by ...
Introduction Graft versus host disease (GVHD) is a life threatening complication of allogeneic hemat...
Despite the increasing use of humanized mouse models to study new approaches of graft-versus-host di...
<div><p>Mice bearing a “humanized” immune system are valuable tools to experimentally manipulate hum...
Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment for hematologic malignan...
Despite considerable progress in allogeneic hematopoietic cell transplantation (allo-HCT) has been a...
AbstractOver the last 50 years, mouse models of bone marrow transplantation have provided the critic...
AbstractChronic graft-versus-host-disease (cGVHD) is a major barrier to successful allogeneic hemato...
Graft-vs-host disease (GVHD) is the most common cause of non-relapse mortality following allogeneic ...
Over the last 50 years, mouse models of bone marrow transplantation have provided the critical links...
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for hematologic malig...
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell trans...
AbstractChronic graft-versus-host-disease (cGVHD) is a major barrier to successful allogeneic hemato...
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell trans...
Bone marrow transplantation (BMT) is the only therapeutic option for many hematological malignancies...
The last 6 decades have seen major advances in the understanding of immunologic diseases, driven by ...
Introduction Graft versus host disease (GVHD) is a life threatening complication of allogeneic hemat...
Despite the increasing use of humanized mouse models to study new approaches of graft-versus-host di...
<div><p>Mice bearing a “humanized” immune system are valuable tools to experimentally manipulate hum...
Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment for hematologic malignan...
Despite considerable progress in allogeneic hematopoietic cell transplantation (allo-HCT) has been a...